Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (121-130 of 284) with videos related to

Pageof 29
Sort By:
European Journal of Radiology|February 13, 2017
Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinibMizuki Nishino, Adrian G Sacher, Leena Gandhi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Cancer|July 26, 2017
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation ConsortiumRathi N Pillai, Madhusmita Behera, Lynne D Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerJohn R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Cost-effectiveness of computed tomography screening for lung cancer in the United StatesPamela M McMahon, Chung Yin Kong, Colleen Bouzan, et al.
Cancer|September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancerAdam H Fox, Raymond U Osarogiagbon, Farhood Farjah, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman, Alison J Holmes, Neal Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Pageof 29

Showing results (121-130 of 284) with videos related to

Sort By:
Pageof 29
European Journal of Radiology|February 13, 2017
Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinibMizuki Nishino, Adrian G Sacher, Leena Gandhi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Cancer|July 26, 2017
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation ConsortiumRathi N Pillai, Madhusmita Behera, Lynne D Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerJohn R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Cost-effectiveness of computed tomography screening for lung cancer in the United StatesPamela M McMahon, Chung Yin Kong, Colleen Bouzan, et al.
Cancer|September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancerAdam H Fox, Raymond U Osarogiagbon, Farhood Farjah, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman, Alison J Holmes, Neal Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Pageof 29